glycodac, daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine
Glycodac, Gliclazide 80 mg, Gliclazide, Glycodac-80 daksh, daksh diabetic and cardiac, daksh pharma panchkula, daksh diabetic and cardiac panchkula, pcd franchise, pcd franchise company in panchkula, daksh group, pharma companies, pharma products, franchise, speciality product
glycodac, daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine
glycodac, daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine
Glycodac, Gliclazide 80 mg, Gliclazide, Glycodac-80 daksh, daksh diabetic and cardiac, daksh pharma panchkula, daksh diabetic and cardiac panchkula, pcd franchise, pcd franchise company in panchkula, daksh group, pharma companies, pharma products, franchise, speciality product
glycodac, daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine

GLYCODAC

TAB GLYCODAC 60 XR (Gliclazide 60 mg (SR)) BILSTER 10 X 10
TAB GLYCODAC-80 (Gliclazide 80 mg) BILSTER 10 X 10
TAB GLYCODAC-M (Gliclazide 80 mg + Metformin 500 mg ) BILSTER 10 X 10
Category: Tag:
Send Enquiry

GLYCODAC Range

Introduction:

The GLYCODAC range offers effective oral antidiabetic therapy based on Gliclazide, a well-established sulfonylurea that stimulates insulin release from pancreatic β-cells. It is suitable for patients with Type 2 Diabetes Mellitus (T2DM) requiring monotherapy or combination therapy to maintain glycemic control. GLYCODAC provides flexible dosing options, including sustained-release and combination formulations, to match various clinical needs.

Each variant is conveniently packaged in blister packs (10 x 10 tablets) to promote patient adherence and consistent dosing.

Product Variants & Composition:

A) GLYCODAC 60 XR
Composition: Gliclazide 60 mg (Sustained Release)
Packaging: Blister | 10 x 10 Tablets

B) GLYCODAC-80
Composition: Gliclazide 80 mg
Packaging: Blister | 10 x 10 Tablets

C) GLYCODAC-M
Composition: Gliclazide 80 mg + Metformin 500 mg
Packaging: Blister | 10 x 10 Tablets

Key Benefits:

  • Gliclazide: A second-generation sulfonylurea that enhances insulin secretion without causing abrupt hypoglycemia.

  • Sustained Release (XR) Formula: Ensures prolonged blood glucose control with once-daily dosing.

  • Gliclazide + Metformin (GLYCODAC-M): Combines insulinotropic and insulin-sensitizing actions for a synergistic glycemic effect.

  • Cardio-safe profile: Gliclazide is recognized for its reduced risk of cardiovascular complications compared to other sulfonylureas.

  • Effective in reducing HbA1c and postprandial glucose levels.

  • Improves β-cell function and insulin sensitivity.

Indications:

  • Type 2 Diabetes Mellitus not adequately managed by diet, exercise, and lifestyle alone.

  • Patients requiring an oral hypoglycemic with or without insulin resistance.

  • Ideal for those who benefit from a sulfonylurea with a safer metabolic profile.

Dosage & Administration:

  • Dosage should be individualized based on patient’s blood glucose levels, therapeutic response, and tolerability.

  • Usually administered once or twice daily with meals to reduce the risk of hypoglycemia.

  • Regular monitoring of fasting glucose, postprandial glucose, and HbA1c is recommended.

Precautions & Warnings:

  • Use with caution in patients with renal or hepatic impairment.

  • Not recommended for Type 1 Diabetes or Diabetic Ketoacidosis.

  • Risk of hypoglycemia, especially with missed meals or overexertion.

  • Avoid alcohol and monitor for signs of allergic reactions or blood disorders.

Possible Side Effects:

  • Hypoglycemia (more likely in elderly or undernourished individuals)

  • Dizziness, headache

  • Gastrointestinal upset

  • Rare: Allergic skin reactions, liver enzyme abnormalities, or blood dyscrasias

Conclusion:

The GLYCODAC range is a trusted solution for individualized glycemic control in T2DM, offering monotherapy and combination therapy options with proven efficacy and safety. Whether patients need a gradual-release formulation or dual-action combination with Metformin, GLYCODAC meets the diverse needs of modern diabetes care.

Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.

For more such product information and similar product category Diabetic

You can also contact us  https://diabetes-cardiac.com/contact-us/

Related products